clinical trial · NCT07519070
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis
Haisco Pharmaceutical Group Co., Ltd.·phase3·not yet recruiting·n = 420
IPFHSK44459HSK44459HSK44459PlaceboPlaceboPlacebo
brief summary
This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).
started
Apr 5, 2026
primary completion
Apr 5, 2028
completion
Dec 30, 2028
last updated
Apr 9, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol